GenSight Biologics

GenSight Biologics appoints Mohamed Genead as chief medical officer

Thursday, May 4, 2017

GenSight Biologics, a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, announced it has appointed Mohamed Genead, M.D., as chief medical officer. Dr. Genead brings more than 15 years of experience to the role, including his most recent role as vice president & global therapeutic area head for Ophthalmology/Retina Gene Therapy at Biogen.

[Read More]

GenSight to add teenage patients in Leber’s hereditary optic neuropathy trial

Tuesday, September 13, 2016

GenSight Biologics, a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, has announced that regulatory agencies and ethics committees in the U.S., France and the U.K., have authorized a protocol amendment to include teenage patients (15-18 years) in RESCUE and REVERSE, two ongoing phase III clinical trials of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy (LHON).

[Read More]